Trade Report: The Public Employees Retirement Association of Colorado Sells shares of Eli Lilly and Co. (LLY)

The Public Employees Retirement Association of Colorado Sells shares of Eli Lilly and Co. (LLY)

Public Employees Retirement Association of Colorado decreased its position in shares of Eli Lilly and Co. (NYSE:LLY) by 5.4% during the second quarter, Holdings Channel reports. The institutional investor owned 207,822 shares of the company’s stock after selling 11,839 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Eli Lilly and were worth $16,366,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. increased its position in Eli Lilly and by 1.1% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 16,219 shares of the company’s stock worth $1,277,000 after buying an additional 180 shares in the last quarter. Quadrant Capital Group LLC increased its position in Eli Lilly and by 34.1% in the second quarter. Quadrant Capital Group LLC now owns 3,437 shares of the company’s stock worth $258,000 after buying an additional 874 shares in the last quarter. Savant Capital LLC increased its position in Eli Lilly and by 1.4% in the second quarter. Savant Capital LLC now owns 7,189 shares of the company’s stock worth $566,000 after buying an additional 100 shares in the last quarter. Sabal Trust CO increased its position in Eli Lilly and by 26.7% in the second quarter. Sabal Trust CO now owns 8,125 shares of the company’s stock worth $640,000 after buying an additional 1,712 shares in the last quarter. Finally, Grandfield & Dodd LLC increased its position in Eli Lilly and by 2.0% in the second quarter. Grandfield & Dodd LLC now owns 7,761 shares of the company’s stock worth $611,000 after buying an additional 150 shares in the last quarter. 74.96% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Co. (NYSE:LLY) traded down 1.61% during trading on Wednesday, hitting $80.49. 2,078,598 shares of the company traded hands. The company’s 50 day moving average is $79.63 and its 200-day moving average is $77.69. Eli Lilly and Co. has a 52 week low of $67.88 and a 52 week high of $88.16. The stock has a market capitalization of $85.13 billion, a PE ratio of 34.69 and a beta of 0.17.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.86. The company earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.90 earnings per share. Analysts predict that Eli Lilly and Co. will post $3.59 earnings per share for the current year.

A number of research firms have recently weighed in on LLY. Leerink Swann reissued a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research report on Sunday. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. BMO Capital Markets reissued a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a research report on Monday, October 3rd. Goldman Sachs Group Inc. raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and increased their target price for the company from $89.00 to $95.00 in a research report on Tuesday, September 27th. Finally, Deutsche Bank AG restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, September 20th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Buy” and an average target price of $97.06.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total transaction of $100,873.08. Following the transaction, the insider now owns 1,300 shares of the company’s stock, valued at $108,108. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 240,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the transaction, the insider now directly owns 126,020,570 shares in the company, valued at approximately $10,443,324,635.90. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment